X4 Pharmaceuticals Announces International Enrollment Sites for Chronic Neutropenia Phase 3 Clinical Trial / The Jeffrey Modell Foundation

X4 Pharmaceuticals a company driven to improve the lives of people with rare diseases of the immune system, announced that it is currently screening patients for enrollment into its global, Chronic Neutropenia Phase 3 clinical trial. The 52-week trial is a multicenter study aiming to enroll 150 participants.

Click here to view list of international Clinical Trial sites.

Headquarters: Learn how JMF is “Doing Something”

Information Booth: Find an Immunologist and information about PI

Library: Educational materials and the 10 Warning Signs

Medical Academy: Access Research, grants, travel grants and more

WJMF News: Read breaking news and view our PSA campaign

Town Hall: Advocate with JMF about important PI topics

Village Park: Apply to WIN or have fun at the Kids Zone

Airport: Fly into our Airport and become a Dream Maker